Briacell Therapeutics Corp. Common Shares - BCTX STOCK NEWS

BriaCell Therapeutics Corp. (Nasdaq: BCTX) has announced alternative voting procedures for its upcoming annual general meeting on January 23, 2025, due to Canada's postal workers strike. The meeting materials are available on SEDAR+ and the company's website. The meeting will cover financial statements review, director elections, and auditor appointment.

Due to postal delays, shareholders are urged to vote before January 21, 2025, 10:00 AM EST. Registered shareholders can obtain voting control numbers via Computershare Shareholder Services. Beneficial shareholders, both NOBOs and OBOs, have specific procedures for accessing their voting materials and submitting votes through designated channels.

BriaCell Therapeutics (Nasdaq: BCTX) has completed its previously announced public offering, raising $5.55 million in gross proceeds. The offering consisted of 7,400,000 common shares and warrants at a combined price of $0.75 per share and associated warrant. The warrants, exercisable at $0.9375 per share, are valid for five years from issuance. ThinkEquity served as the sole book-running manager for the offering.

The company plans to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives. The securities were offered under BriaCell's effective shelf registration statement on Form S-3, which was declared effective on January 31, 2024.

BriaCell Therapeutics (Nasdaq: BCTX) presented positive results from their phase 2 study of Bria-IMT™ plus CPI regimen at the 2024 San Antonio Breast Cancer Symposium. Using CD8 ImmunoPET imaging technology, the study demonstrated the treatment's ability to turn 'cold' tumors 'hot' by increasing cancer-fighting CD8+ T cells infiltration in metastatic breast cancer tumors and lymph nodes.

Key findings from 6 heavily pre-treated patients after 27 weeks included: treatment was generally well-tolerated, tumor marker reduction in 2 patients, 50% of patients showed decreased neutrophil/lymphocyte ratio, and evidence of immune system activation. These results support BriaCell's ongoing pivotal Phase 3 study in metastatic breast cancer.

BriaCell Therapeutics (Nasdaq: BCTX) has announced the pricing of a $5.5 million public offering, consisting of 7,400,000 common shares and warrants. The combined offering is priced at $0.75 per share and associated warrant. The warrants, exercisable at $0.9375 per share, will be valid for five years upon issuance.

The offering, expected to close on December 13, 2024, is being managed by ThinkEquity as the sole book-running manager. The company plans to use the proceeds for working capital requirements, general corporate purposes, and advancing business objectives. The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC.

BriaCell Therapeutics (Nasdaq: BCTX) has announced plans for an underwritten public offering of common shares and warrants. ThinkEquity will serve as the sole book-running manager for the offering. The company intends to use the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives.

The securities will be offered through a shelf registration statement on Form S-3 filed with the SEC. The offering's completion, size, and terms are subject to market conditions. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.

BriaCell Therapeutics (NASDAQ: BCTX) presented impressive Phase 2 clinical trial results for its Bria-IMT™ cancer immunotherapy at the 2024 SABCS®. The study showed a median overall survival of 13.4 months for Phase 2 patients treated with the Phase 3 formulation, doubling the survival rate compared to literature data. Notably, patients treated since 2022 achieved 15.6 months median survival.

The trial included 54 heavily pre-treated metastatic breast cancer patients, with 37 receiving the current Phase 3 formulation. Particularly significant was the 13.7 months median survival in patients with CNS metastasis. The treatment demonstrated strong safety with no toxicity-related discontinuations, and showed promising results especially in HER2+ and HR+/HER2- patient subsets.

BriaCell Therapeutics (Nasdaq: BCTX) received positive safety review from the Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. The DSMB recommended continuation of the study without modifications, marking a significant milestone for the company's FDA Fast Track Designated trial. The independent review board found no safety concerns in enrolled patients, supporting BriaCell's advancement of its novel immunotherapy combination treatment.

BriaCell Therapeutics (Nasdaq: BCTX) will present positive survival data for its Bria-IMT™ plus immune checkpoint inhibitor combination therapy in metastatic breast cancer at SABCS® 2024. The Phase 2 study showed a median overall survival of 13.4 months, exceeding historical controls, with final calculations pending as many patients remain alive. The therapy demonstrated promising results across all breast cancer subtypes, with a 9.5% objective response rate and 55% clinical benefit rate. The study included 54 patients total, with positive outcomes observed in patients with low circulating tumor cell counts and positive delayed type hypersensitivity responses.

BriaCell Therapeutics, a clinical-stage biotechnology company specializing in immunotherapies for cancer, has announced the resignation of Mr. Marc Lustig from its Board of Directors. The resignation is effective immediately. The company expressed gratitude for Mr. Lustig's significant contributions during his tenure.